{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:19:57Z","timestamp":1784762397734,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018090","name":"Bayer Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ijcard.2024.131786","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T06:57:50Z","timestamp":1705647470000},"page":"131786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Comparative efficacy of vericiguat to sacubitril\/valsartan for patients with heart failure reduced ejection fraction: Systematic review and network meta-analysis"],"prefix":"10.1016","volume":"400","author":[{"given":"Dong-Won","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ho","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungae","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-Soon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Chan","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Kyeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ijcard.2024.131786_bb0005","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ijcard.2024.131786_bb0010","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","article-title":"Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week","volume":"76","author":"Emdin","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"18","key":"10.1016\/j.ijcard.2024.131786_bb0015","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ijcard.2024.131786_bb0020","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.131786_bb0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejps.2018.11.037","article-title":"Sacubitril\/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation","volume":"128","author":"Mochel","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijcard.2024.131786_bb0030","series-title":"NECA\u2019s Methodological Guide for Economic Evaluation of Medical Intervention","author":"Kim","year":"2021"},{"issue":"2","key":"10.1016\/j.ijcard.2024.131786_bb0035","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/S0266462308080240","article-title":"Direct versus indirect comparisons: a summary of the evidence","volume":"24","author":"Gartlehner","year":"2008","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"2","key":"10.1016\/j.ijcard.2024.131786_bb0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11606-010-1513-8","article-title":"Understanding equivalence and noninferiority testing","volume":"26","author":"Walker","year":"2011","journal-title":"J. Gen. Intern. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2024.131786_bb0045","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10557-020-07099-2","article-title":"Relative efficacy of Sacubitril-valsartan, Vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis","volume":"35","author":"Aimo","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcard.2024.131786_bb0050","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2024.131786_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ijcard.2024.131786_bb0060","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jchf.2016.05.002","article-title":"Efficacy of Sacubitril\/valsartan relative to a prior decompensation: the PARADIGM-HF trial","volume":"4","author":"Solomon","year":"2016","journal-title":"JACC Heart Fail."},{"issue":"11","key":"10.1016\/j.ijcard.2024.131786_bb0065","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2024.131786_bb0070","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal pro-B-type natriuretic peptide and clinical outcomes: Vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131786_bb0075","series-title":"Guidance for industry non-inferiority clinical trials","author":"Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Food and Drug Administration, U.S. Department of Health and Human Services","year":"2016"},{"issue":"8","key":"10.1016\/j.ijcard.2024.131786_bb0080","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/bcp.13280","article-title":"Defining the noninferiority margin and analysing noninferiority: an overview","volume":"83","author":"Althunian","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.ijcard.2024.131786_bb0085","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat global study in subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur. J. Heart Fail."},{"issue":"21","key":"10.1016\/j.ijcard.2024.131786_bb0090","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ijcard.2024.131786_bb0095","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324001165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324001165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:05:15Z","timestamp":1759093515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324001165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":19,"alternative-id":["S0167527324001165"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131786","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of vericiguat to sacubitril\/valsartan for patients with heart failure reduced ejection fraction: Systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131786"}}